Plain-English translation of NCT06787144 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a first-in-human study of a new medication called designed to treat chronic myeloid leukemia (CML), a type of blood cancer. Researchers are testing this treatment in people whose leukemia has stopped responding to previous standard drugs or who cannot tolerate them. The study will first find the safest dose, then test that dose in a larger group to understand how well the medication works and what side effects it causes.
Many people with chronic myeloid leukemia eventually stop responding to the medications currently available, or experience unbearable side effects. This medication may offer a new option for those patients, particularly those with a specific genetic change called T315I that makes the cancer especially hard to treat.
You likely qualify if…
You likely don't qualify if…
The study has two parts. First, small groups of participants will receive increasing doses of the medication to find the safest level (this is called dose escalation). Once a safe dose is found, a second group of about 6 participants per dose level will take the medication at that dose. Throughout the study, you will have blood tests to check your blood counts, liver and kidney function, and measure how well the medication is controlling your leukemia. Researchers will also monitor you closely for any side effects.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
Japan